Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion type Assertion NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_head.
- NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion description "[Patients with Basal (90), HER2 (119), Luminal B (98) and Luminal A (76) tumor subtypes had a median TPDBM of 27.5, 35.8, 47.4 and 54.4 months (p < 0.01), median survival from PD of 39.6, 66.4, 90.3 and 72.7 months (p < 0.01) and median survival from BM of 7.3, 17.9, 22.9 and 10.0 months (p < 0.01), respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_provenance.
- NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion evidence source_evidence_literature NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_provenance.
- NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion SIO_000772 23462853 NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_provenance.
- NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion wasDerivedFrom befree-2016 NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_provenance.
- NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_assertion wasGeneratedBy ECO_0000203 NP1058024.RA_3CiLwTdcKqZCrAa39LXj3bJFcR0eNe9yKCbzKPV6t0130_provenance.